Download PDF
Thromb Haemost 1995; 74(04): 1025-1028
DOI: 10.1055/s-0038-1649873
Original Article
Clinical Studies
Schattauer GmbH Stuttgart

Influence of Various Heparin Preparations on Lipoproteins in Hemodialysis Patients: A Multicentre Study

Florian Kronenberg
1   The Institute of Medical Biology and Human Genetics, University of Innsbruck, Austria
,
Paul König
2   The Innsbruck University Hospital, Department of Clinical Nephrology, Austria
,
Ulrich Neyer
3   The Feldkirch Hospital, Austria
,
Martin Auinger
4   The Lainz Hospital Vienna, Austria
,
Andreas Pribasnig
5   The St. Pölten Hospital, Austria
,
Thomas Meisl
6   The Wilhelminenspital Vienna, Austria
,
Georg Pinter
7   The Klagenfurt Hospital, Austria
,
Hans Dieplinger
1   The Institute of Medical Biology and Human Genetics, University of Innsbruck, Austria
› Author Affiliations
Further Information

Publication History

Received 24 March 1995

Accepted after resubmission 31 May 1995

Publication Date:
09 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Recent studies have indicated controversial effects of low molecular weight heparin (LMWH) on lipid metabolism in patients on chronic hemodialysis as compared to unfractionated heparin (UFH).

We therefore conducted a cross-sectional multicentre study comparing 153 patients treated with LMWH and 153 patients with UFH, matched for sex, age and diabetes mellitus. Both groups have been treated with LMWH or UFH for six months or longer (14.9 vs.23.4 months). We observed no differences between the UFH and LMWH treatment groups for total cholesterol, LDL cholesterol, triglycerides, apoB, apoA-IV or Lp(a). The only significant differences were seen for HDL cholesterol and the corresponding apolipoprotein apoA-I, which were significantly higher in the UFH group (HDL cholesterol: 0.97 ± 0.35 mM/l vs. 0.87 ± 0.37 mM/l, p<0.05; apoA-I 1.23 ± 0.27 g/l vs. 1.15 ± 0.27 g/l, p <0.05).

We conclude that the results of studies investigating the influence of LMWH on lipid metabolism are as heterogeneous as the substances themselves. This challenges the beneficial influence supposedly had by LMWH preparations on lipid metabolism.

 

  • References

  • 1 Appel G. Lipid abnormalities in renal disease. Kidney Int 1991; 39: 169-183
    CrossrefPubMedGoogle Scholar
  • 2 Dieplinger H, Lackner C, Kronenberg F, Sandholzer C, Lhotta K, Hoppichler F, Graf H, König P. Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a). J Clin Invest 1993; 91: 397-401
    CrossrefPubMedGoogle Scholar
  • 3 Kronenberg F, Kathrein H, König P, Neyer U, Sturm W, Lhotta K, Grochenig E, Utermann G, Dieplinger H. Apolipoprotein(a) phenotypes predict the risk for carotid atherosclerosis in patients with end-stage renal disease. Arterioscler Thromb 1994; 14: 1405-1411
    CrossrefPubMedGoogle Scholar
  • 4 Weintraub M, Rassin T, Eisenberg S, Ringel Y, Grosskopf I, Iaina A, Charach G, Liron M, Rubinstein A. Continuous intravenous heparin administration in humans causes a decrease in serum lipolytic activity and accumulation of chylomicrons in circulation. J Lipid Res 1994; 35: 229-238
    PubMedGoogle Scholar
  • 5 Williams KJ, Petrie KA, Brocia RW, Swenson TL. Lipoprotein lipase modulates net secretory output of apolipoprotein B in vitro. A possible pathophysiologic explanation for familial combined hyperlipidemia J Clin Invest 1991; 88: 1300-1306
    CrossrefPubMedGoogle Scholar
  • 6 Schrader J, Stibbe W, Armstrong VW, Kandt M, Muche R, Kostering H, Seidel D, Scheler F. Comparison of low molecular weight heparin to standard heparin in hemodialysis/hemofiltration. Kidney Int 1988; 33: 890-896
    CrossrefPubMedGoogle Scholar
  • 7 Deuber HJ, Schulz W. Reduced lipid concentrations during four years of dialysis with low molecular weight heparin. Kidney Int 1991; 40: 496-500
    CrossrefPubMedGoogle Scholar
  • 8 Nikolay J, Schulz E, Traut G, Nieth H, Biesel E, Zielke E. The effect of anticoagulation with low-molecular-weight heparin upon increased triglyceride and cholesterol concentrations in chronic hemodialysis patients. Nieren- und Hochdruckkrankheiten 1990; 19: 519-523
    PubMedGoogle Scholar
  • 9 Schmitt Y, Schneider H. Low-molecular-weight heparin (LMWH): influence on blood lipids in patients on chronic haemodialysis. Nephrol Dial Transplant 1993; 8: 43842
    PubMedGoogle Scholar
  • 10 Hombrouckx R, Devos JY, Larno L. Standard heparin (SH) versus 3 low-molecular-weight heparins (LMWH) in chronic dialysis. Nephrol Dial Transplant 1994; 9: 988 (Abstract)
    PubMedGoogle Scholar
  • 11 Kronenberg F, König P, Lhotta K, Steinmetz A, Dieplinger H. Low molecular weight heparin does not necessarily reduce lipids and lipoproteins in hemodialysis patients. Clin Nephrol 1995; 43: 399-404
    PubMedGoogle Scholar
  • 12 Spaia S, Pangidis P, Kanetidis D, Mavropoulou E, Vakaloudi A, Karagiannis A, Vayonas G. Longterm effects of low-molecular-weight heparin in hemodialyzed patients. Hellenic Nephrology 1994; 6: 426-430
    PubMedGoogle Scholar
  • 13 Kronenberg F, König P, Neyer U, Auinger M, Pribasnig A, Lang U, Reitinger J, Pinter G, Utermann G, Dieplinger H. Multicentre study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 1995; 6: 110-120
    PubMedGoogle Scholar
  • 14 Kronenberg F, Lobentanz E-M, König P, Utermann G, Dieplinger H. Effect of sample storage on the measurement of lipoprotein(a), apolipoproteins B and A-IV, total and high-density lipoprotein cholesterol and triglycerides. J Lipid Res 1994; 35: 1318-1328
    CrossrefPubMedGoogle Scholar
  • 15 Helger R, Rindfrey H, Hilgenfeldt J. Eine Methode zur direkten Bestimmung des Creatinins in Serum und Ham ohne Enteiweissung nach einer modifizierten Jaffe-Methode. Z klin Chemie klin Biochem 1974; 12: 344-351
    PubMedGoogle Scholar
  • 16 Doumas BT, Watson WA, Biggs HG. Albumin standards and the measurement of serum albumin with bromcresol green. Clin Chim Acta 1971; 31: 87-91
    CrossrefPubMedGoogle Scholar
  • 17 Szasz G, Weimann G, Stähler F, Wahlefeld A-W, Persijn J-P. New substrates for measuring gamma-glutamyl transpeptidase activity. Z klin Chemie klin Biochem 1974; 12: 228-235
    PubMedGoogle Scholar
  • 18 Green D, Hirsh J, Heit J, Prins M, Davidson B, Lensing AW A. Low molecular weight heparin: a critical analysis of clinical trials. Pharmacological Reviews 1994; 46: 89-109
    PubMedGoogle Scholar
  • 19 Etienne J, Millot F, Pieron R, Laruelle P. Release of LPL activity after intravenous injection of a low molecular weight heparin. Br J Clin Pharmacol 1983; 16: 712-714
    CrossrefPubMedGoogle Scholar
  • 20 Persson E, Nordenström J, Nilsson-Ehle P. Plasma kinetics of lipoprotein lipase and hepatic lipase activities induced by heparin and a low molecular weight heparin fragment. Scand J Clin Lab Invest 1987; 47: 151-155
    CrossrefPubMedGoogle Scholar
  • 21 Meraihi Z, Lutz O, Frey A, Bach AC. In vivo and in vitro release of lipoprotein lipase and hepatic lipase by low molecular weight heparins. Arch int Pharmacodyn 1989; 297: 286-293
    PubMedGoogle Scholar
  • 22 Liu G, Bengtsson-Olivecrona G, Ostergaard P, Olivecrona T. Low-Mrheparin is as potent as conventional heparin in releasing lipoprotein lipase, but is less effective in preventing hepatic clearance of the enzyme. Biochem J 1991; 273: 747-752
    CrossrefPubMedGoogle Scholar
  • 23 Liu G, Hultin M, Ostergaard P, Olivecrona T. Interaction of size-fractionated heparins with lipoprotein lipase and hepatic lipase in the rat. Biochem J 1992; 285: 731-736
    CrossrefPubMedGoogle Scholar
  • 24 Weidmann P, Decourten M, Ferrari P, Bohlen L. Serum Lipoproteins During Treatment with Antihypertensive Dmgs. J Cardiovasc Pharmacol 1993; 22 Suppl 6: S98-S105
    PubMedGoogle Scholar
  • 25 Stenvinkel P. Low molecular weight heparin – does it favourably affect lipid levels. Nephrol Dial Transplant 1995; 10: 16-18
    CrossrefPubMedGoogle Scholar